Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | EIF4A1 | P60842 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157269 | 0.82 | MAPT (0.47) | MAPTALDH1A1LMNACYP19A1RAB9A | |
| SCHEMBL6983789 | 0.80 | LMNA (0.45) | MAPTALDH1A1LMNARAB9AL3MBTL1 | |
| SCHEMBL6985505 | 0.80 | MAPT (0.73) | MAPTALDH1A1LMNARAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL6986383 | 0.79 | ALDH1A1 (0.40) | MAPTALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL28352404 | 0.79 | LMNA (0.44) | MAPTALDH1A1LMNARAB9AL3MBTL1 | |
| SCHEMBL2893781 | 0.75 | PIM1 (0.62) | MAPTALDH1A1LMNARAB9AL3MBTL1 | |
| SCHEMBL6979379 | 0.73 | MAPT (0.55) | MAPTRAB9AL3MBTL1NPC1MEN1 | |
| SCHEMBL27915784 | 0.72 | MAPT (0.60) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6987618 | 0.72 | MAPT (0.54) | MAPTLMNARAB9AL3MBTL1NPC1 | |
| SCHEMBL6983248 | 0.71 | MAPT (0.51) | MAPTALDH1A1LMNARAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1292585-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | SQLE, CYP17A1, ACOX1 | MAPT 4824/4885ALDH1A1 1026/4885LMNA 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.